In the present study, we used TCGA-COAD, Local-COAD, and an immunotherapy cohort to explore the effect of PI3K/Akt pathway mutations on the prognosis of colon adenocarcinoma patients receiving ICI treatments. This evidence concerns the gene AKT1 and colon adenocarcinoma.